Abstract. The development of cisplatin resistance in human cancers is controlled by multiple genes and leads to therapeutic failure. Hypermethylation of specific gene promoters is a key event in clinical resistance to cisplatin. Although the usage of multiple promoters is frequent in the transcription of human genes, the role of alternative promoters and their regulatory sequences have not yet been investigated in cisplatin resistance genes. In a new approach, we hypothesized that human cancers exploit the specific transcription factor-binding sites (TFBS) and CpG islands (CGIs) located in the alternative promoters of certain genes to acquire platinum drug resistance. To provide a useful resource of regulatory elements associated with cisplatin resistance, we investigated the TFBS and CGIs in 48 alternative promoters of 14 hypermethylated cisplatin resistance genes previously reported. CGIs prone to methylation were identified in 28 alternative promoters of 11 hypermethylated genes. The majority of alternative promoters harboring CGIs (93%) were clustered in one phylogenetic subclass, whereas the ones lacking CGIs were distributed in two unrelated subclasses. Regulatory sequences, initiator and TATA-532 prevailed over TATA-8 and were found in all the promoters. B recognition element (BRE) sequences were present only in alternative promoters harboring CGIs, but CCAAT and TAACC were found in both types of alternative promoters, whereas downstream promoter element sequences were significantly less frequent. Therefore, it was hypothesized that BRE and CGI sequences co-localized in alternative promoters of cisplatin resistance genes may be used to design molecular markers for drug resistance. A more extensive knowledge of alternative promoters and their regulatory elements in clinical resistance to cisplatin is likely to usher novel avenues for sensitizing human cancers to treatment.
Introduction
The success of platinum drugs in the treatment of various types of cancer has been challenged by the hamper of intrinsic and acquired resistance. Cell and molecular biology research over several decades has provided insight into this problem and has demonstrated that alterations in drug influx and efflux, detoxification via glutathione and glutathione transferases and enhanced DNA repair (1) (2) (3) are all involved, either singly or in combination, in cisplatin resistance. However, it remains puzzling that genomic expression patterns of platinum-sensitive̸-resistant determinants in several cell lines, including squamous cell carcinoma of the head and neck, bladder and ovarian cancers, do not always correlate with the results of biochemical analyses (4) (5) (6) . Additionally, epigenetic changes in the DNA methylation profiles during cancer development are associated with the acquisition of cisplatin resistance (6) (7) (8) (9) . However, the problem of platinum resistance at the genomic and epigenomic levels has not been clearly defined. Therefore, it is paramount to gain a better understanding of gene expression machinery components that control platinum resistance genes. A promising approach to , RUIWEN ZHANG 6 and KALKUNTE S. SRIVENUGOPAL these questions appears to be the characterization of regulatory elements, CpG islands (CGIs) and transcription factor-binding sites (TFBS) in alternative promoters of genes that have been validated and their association with cisplatin resistance proven. It has been well established that alternative promoters are involved in the transcription of nearly half of all eukaryotic genes and are considered one of the main molecular characteristics of eukaryotic genomes (10, 11) . Overall, alternative promoters have been suggested to add significant flexibility and greater diversity to the regulation of gene expression (10) (11) (12) (13) (14) (15) (16) . The functional significance of alternative promoters and their role in disease development and progression remains unclear, except for a few well characterized genes, such as the tumor suppressor p53, lymphoid enhancer-binding factor 1, insulin growth factor 2 and guanine nucleotide-binding protein α-stimulating genes, where these sequences are aberrantly activated, developmentally regulated or silenced (11) . In addition, alternative promoters have been shown to regulate the expression of paired box homeotic gene 6 in various tissue types and play crucial roles in the development of the eye, brain, olfactory system and endocrine pancreas (17) .
The TFBS and the CGIs targeted for DNA methylation, significantly affect the functional activities of alternative promoters (6) (7) (8) (9) 18, 19) . To date, the role and molecular characteristics of alternative promoters have not been investigated in platinum drug resistance. The present study mapped the distribution of TFBS and CGIs in 48 alternative promoters involved in the regulation of 14 hypermethylated genes, known to be associated with the development of cisplatin resistance.
Materials and methods
Alternative promoters of cisplatin resistance genes. A total of 14 genes known to contribute to cisplatin resistance and to be specifically hypermethylated in resistant cell lines, but not in the sensitive parental cell lines (9) , were selected for this study. The genes were screened for the presence of alternative promoters and regulatory elements (CGIs and TFBS) within these sequences. The chromosomal map locations of cisplatin genes were searched in the GenBank database (http://www. ncbi.nlm.nih.gov/genbank/) and the alternative promoters for each gene were searched in the Transcriptional Regulatory Element Database (TRED; https://cb.utdallas.edu/cgi-bin/ TRED/tred.cgi?process=home). The length of the promoter sequence was set to 1,000 base pairs (bps), which were numbered along the sequence of the promoter relative to the transcription start site (TSS). The sequence of bps upstream the TSS was numbered with a negative sign, whereas downstream bases were identified with a positive sign.
Search for regulatory elements in the alternative promoters.
The alternative promoters of 14 cisplatin resistance genes were analyzed for TFBS, namely, TATA-8 (TATAWAWR) and TATA-532 (HWHWWWWR, excluding HTYTTTWR, CAYTTTWR, MAMAAAAR and CTYAAAAR) elements, initiator (INR; YYANWYY), CCAAT and its inverted sequence TAACC, B recognition element (BRE; SSRCGCC) and downstream promoter element (DPE; RGWCGTG) sequences (20, 21) . CGIs in alternative promoters were searched in a 100-bp window (N=100) moving across the sequence at 1-bp intervals. The parameter sets used to search for CGIs in the alternative promoters were as follows: observed/expected (O/E) CpG ≥0.6 and %GC >55% (22) (23) (24) (25) . The O/E ratio for CpG was calculated according to the equation reported by Gardiner-Garden and Frommer (22) .
Construction of phylogenetic tree.
To investigate the evolutionary associations among the 48 alternative promoter sequences and to group the related sequences into specific categories, a phylogenetic tree was constructed using the Phylogenetic Tree application in the MATLAB Bioinformatics toolbox to probe the interrelationships and linking the tree nodes. The alternative promoter sequences and their derivatives were drawn using a hierarchical diagram.
Statistical analysis. The promoter sequences were analyzed using Perl, C++ and Excel software. The independence of each promoter element was examined using the Fisher's exact probability test.
Results

Hypermethylated genes in acquired cisplatin resistance.
Chang et al (9) published an elegant study of specific genes that selectively undergo methylation in cisplatin-resistant cell lines, but not in their cisplatin-sensitive isogenic parent cell counterparts. The authors found that a set of 14 genes were silenced in the cisplatin-resistant cells and confirmed that promoter methylation, as determined by sodium bisulfite sequencing, accounted for the lack of gene expression. A number of these genes were also reactivated by azacytidine treatment of resistant cells (9) . We used this panel of methylated genes for analysis of alternative promoters and their regulatory characteristics in cisplatin resistance. A list of these genes and their designations is provided in Table I . We also mapped the locations of these genes to their chromosomes and these sites are represented in Table I .
Genomic context of alternative promoters of cisplatin hypermethylated genes.
A search through TRED identified 48 promoters for the 14 hypermethylated cisplatin resistance genes reported by Chang et al (9) . These promoters were analyzed to identify the CGIs and TFBS ( Fig. 1 and Table II ). The number of identified alternative promoters for each gene varied between 2 and 6 ( Fig. 1A) and were located on 9 chromosomes (Fig. 1B) . Chromosome 1 and the long arm 'q' were found to host a higher number of genes and alternative promoters compared to other chromosomes and short arms (Fig. 1B) . Of the 14 cisplatin resistance genes, 5 (35.71%) were located on chromosome 1, while of all the promoters investigated, 18 (37.5%) were located on this chromosome. However, the distributions of alternative promoters and genes were almost equal on forward and reverse strands of the chromosomes: 6 genes (43%) were located on the reverse strands and 8 genes (57%) on the forward strands (Fig. 1C) ; 26 promoters (54%) were on the reverse strands and 22 (46%) on the forward strands (Fig. 1D) .
CGIs and TFBS. CGIs were identified in 28 alternative promoters of 11 cisplatin resistance genes, while 3 genes, namely the C4-binding protein β (C4BPB), chromosome 8 open reading frame 4 (C8orf4) and cytidine deaminase (CDA) genes, exhibited no CGIs (Table II) . As shown in Table II , the INR and TATA-532 sequences prevailed over TATA-8 sequences. We also observed that the alternative promoters of cisplatin resistance genes were rich in TATA-8 and TATA-532 sequences, although these varied significantly in their frequencies. For example, the four promoters of opsin 3 (OPN3), namely 44257, 2157, 114168 and 118881, which lack CGIs, contained 13-35 TATA-532 elements. Our analysis also demonstrated that each of two promoters, melanoma cell adhesion molecule (MCAM)-117653 (lacked CGI) and S100P-31251 (harbored two CGIs), contained 10 TATA-8 sequences. Furthermore, the alternative promoters that harbored CGIs contained TATA-532 sequences in a wide range, from 1 to 22. The CCAAT and its inverted sequence TAACC, BRE and DPE sequences were not as frequent as INR and TATA-532 sequences. Another interesting observation was associated with BRE sequences: we noticed that the identified 48 BRE sequences were present G0S2, G0/G1 switch 2; LAMB3, laminin β3; MCAM, melanoma cell adhesion molecule; OPN3, opsin 3; S100P, S100 calcium-binding protein P; SAT1, spermidine̸spermine N1 acetyltransferase 1; TM4SF1, transmembrane 4 L six family member 1; TUBB2A, tubulin β2A class IIa.
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in 20 promoters of 9 cisplatin genes that harbored CGIs and were absent in other alternative promoters that lacked CGIs.
Phylogenetic tree analysis of alternative promoter sequences.
A phylogenetic tree was created from a set of 48 alternative promoter sequences of the 14 cisplatin resistance genes (Fig. 2) . Two main clustering patterns were observed, namely A and B, which may be further divided into subclasses and secondary classes within each category. The first main class (A) included 38 alternative promoters and the second main class (B) included 10 promoters. Furthermore, the first main class (A) may be divided into two subclasses, namely C and D; subclass C contained 30 alternative promoters, of which 26 contained CGIs. Groups E and F were identified in subclass C, which were represented by 19 The evolutionary distances between the two major classes A and B and subclasses C and D were in the range of 0.0125 and 0.03125, respectively, exhibiting weak evolutionary ties between them; however, stronger ties were observed among the alternative promoters in group E and F within subclass C, which were composed mainly from alternative promoters with CGIs (93%). The alternative promoters that lacked CGIs were distributed in two unrelated groups, B and D.
Discussion
We selected a panel of genes specifically known to undergo methylation in cisplatin-resistant cell lines (9) and characterized the alternative promoters and regulatory sequences associated therewith. The exact mechanisms by which these genes contribute to cisplatin resistance has not been fully elucidated; however, a number of these were shown to be inducible by cisplatin treatment in sensitive cells and silenced in sensitive isogenic cells (9) . Recent findings support a prominent role for alternative promoters in cell type and human tissue type-specific gene expression (26) . Considering that the transcription machinery utilizes alternative promoters for regulating differential transcription (10, 16) and the aberrant use of one alternative promoter over another may result in disease, including cancer (11), we hypothesized that cisplatin resistance may be mediated by a differential usage of alternative promoters with variable regulatory sequences, TFBS and CGIs. Transcription factors and their binding sites in a given promoter are key elements in controlling the rate and extent of mRNA synthesis (19, 27) . However, the interaction between transcription factors and cis-regulatory modules, which contain the TFBS in promoter sequences, has not been clearly determined (27) (28) (29) (30) (31) (32) (33) . Seven types of TFBS, namely INR, TATA-8, TATA-532, BRE, DPE, CCAAT and TAACC are well recognized (20, 21) . Our results demonstrated that 11 alternative promoters have TATA-8 sequences and 47 promoters contain TATA-532 sequences. It has been reported that ~76% of human core promoters lack TATA-like elements (20) and only 10-20% of promoters contain the TATA sequences (34) . Of note, our study was not restricted to core Promoter ID  INR  T8  T532  CCAAT  TAACC  BRE  DPE  CGIs   ALCAM  114029  5  0  5  1  0  1  1  +  29583  7  0  7  1  0  1  0  +  29584  11  0  8  0  0  0  0  +  B4GALT1  42895  6  0  1  0  2  4  0  +  113955  5  0  18  0  0  0  0  -C4BPB  1813  12  0  15  0  1  0  0  -1814  11  0  11  0  1  0  0  -113384  12  0  15 +  2379  13  1  13  3  3  0  0  -113034  6  0  7  1  1  0  0  -MCAM  7410  4  0  0  0  0  3  0  +  7411  4  0  2  0  2  0  0  +  117653  5  10  45  0  0  0  0  -OPN3  2156  7  0  3  1  0  5  0  +  44257  12  0  13  0  0  0  0  -2155  7  0  3  1  0  5  0  +  2157  14  0  28  1  1  0  0  -114168  8  2  27  2  1  0  0  -118881  13  1  35  1  0  0  0  -S100P  31250  6  0  4  0  0  0  0  +  31251  4  10  50  0  0  0  0  +  117263  3  0  4  0  0  0  0  -SAT1  43141  6  0  9  1  1  3  0  +  43140  6  0  9  1  1  3  0  +  115065  6  0  9  1  1  3  0  +  TM4SF1  30388  8  0  15  2  0  0  0  -30389  8  0  14  2  0  0  0  -30390  7  0  14  2  0  0  0  -30391  10  0  2  0  2  0  0  +  30392  11  0  6  0  0  1  0  +  118807  7  1  33  2  0  0  0  -TUBB2A  37269  6  1  1  0  0  3  0  +  37270  6  1  1  0  0  3  0  +  37271  6  1  1  0  0  3  0  +  37272  10  0  14  1  0  0  0  +  113646  8  0  22  0  0  2  0  +   a For gene description, see Table I . TFBS: T8, TATAWAWR; T532, HWHWWWWR (excluding HTYTTTWR, MAMAAAAAR and CTYAAAAR); BRE, SSRCGCC; DPE, RGWCGTG; INR, YYANWYY; CCAAT and its inverted sequence TAACC (20, 21) . Parameter sets used to search for CGIs in the alternative promoters: observed/expected CpG ≥0.6 and %GC >55% (22) (23) (24) (25) (21, 36) . As the mechanism associated with cisplatin resistance is multifactorial (1-3), our results suggest that the genes encoding cisplatin resistance harbor more than one option to initiate their transcripts to enhance the efficiency of mRNA production. It has been well documented that CGIs are prone to DNA methylation and this epigenetic mechanism is associated with gene silencing, initiation and maintenance of malignancy and drug resistance (6) (7) (8) (9) (37) (38) (39) . Hypermethylation in CGIs and subsequent gene inactivation contributes to cisplatin resistance (9), as described earlier in this study. In the present study, we demonstrated that 11 out of the 14 genes reported by Chang et al (9) have 28 promoters harboring CGIs. However, the remaining 3 genes, namely C4BPB, C8orf4 and CDA, lacked discernible CGIs, raising the possibility of other mechanisms. The majority of alternative promoters harboring CGIs (93%) were clustered in one phylogenetic subclass, indicating relatively strong evolutionary ties among them. Thus, it may be hypothesized that the use of promoters with less frequent DNA methylation hotspots may assist the genes in escaping the epigenetic modifications and enable continued and efficient expression. Furthermore, we demonstrated that BRE and CGI sequences co-localized in the alternative promoters of cisplatin resistance genes (Table II) and this property may be utilized to design molecular markers for resistance to cisplatin and/or drugs. Such an approach will involve designing specific primers for amplifying DNA sequences that include BRE and a downstream segment of alternative promoter and a short exon region of the gene in question. A more detailed understanding of the functionality of the alternative promoters in cisplatin resistance is likely to have other applications; for example, it may be possible to design novel anticancer drugs that interact with specific promoter sequences, e.g., G-rich sequences which may form DNA G-quadruplexes (40) (41) (42) . In addition, future research may make use of novel synthetic biology methods to build molecular models of various components of alternative promoters (43) (44) (45) (46) to overcome drug resistance and enable more effective and personalized cancer therapies.
